TNC:NYSETennant Company Analysis
Data as of 2026-08-01 - not real-time
$84.03
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Tennant Company (TNC) trades at $84.03, just below its 20‑day SMA (86.08) and 50‑day SMA (86.44), with a neutral price trend but a bearish MACD histogram (-0.37) and RSI at 44, suggesting limited upside momentum. The stock’s forward PE of 13.1 contrasts sharply with a trailing PE of 50, far above the industry average of 30.9, while a discounted‑cash‑flow model values the shares around $26, highlighting a stark valuation disconnect. Meanwhile, the company faces a federal securities investigation tied to a problematic ERP rollout, adding regulatory headwinds to already thin operating margins (1.7% gross, 2.5% profit) and a modest revenue growth rate of 2.7%.
The balance sheet shows a debt‑to‑equity of 73.6% and a payout ratio of 72%, raising concerns about dividend sustainability despite a 1.48% yield. Volatility is elevated at 32% over the past 30 days, though beta (0.81) suggests lower market sensitivity. With support near $78.25 and resistance at $89.97, the stock sits in a narrow range while investors weigh the upside to analyst targets (~$94) against the heavy valuation and operational risks.
The balance sheet shows a debt‑to‑equity of 73.6% and a payout ratio of 72%, raising concerns about dividend sustainability despite a 1.48% yield. Volatility is elevated at 32% over the past 30 days, though beta (0.81) suggests lower market sensitivity. With support near $78.25 and resistance at $89.97, the stock sits in a narrow range while investors weigh the upside to analyst targets (~$94) against the heavy valuation and operational risks.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Federal securities investigation increasing regulatory risk
- Bearish MACD and neutral trend limiting upside
- Current valuation (PE 50) far above industry norms
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Potential operational recovery after ERP issues
- Dividend yield of 1.48% may attract income seekers
- Analyst target price (~$94) implies modest upside
Long Term
> 3 yearsCautious
Model confidence: 8/10
Key Factors
- Sustained high leverage and weak profitability
- Persistent valuation gap (DCF $26 vs market $84)
- Long‑term regulatory and execution risk
Key Metrics & Analysis
Financial Health
Revenue Growth2.70%
Profit Margin2.55%
P/E Ratio50.0
ROE5.33%
ROA2.99%
Debt/Equity73.64
P/B Ratio2.7
Op. Cash Flow$34.2M
Free Cash Flow$52.5M
Industry P/E30.9
Technical Analysis
TrendNeutral
RSI43.9
Support$78.25
Resistance$89.97
MA 20$86.08
MA 50$86.44
MA 200$78.17
MACDBearish
VolumeIncreasing
Fear & Greed Index92.88
Valuation
Fair Value$26.20
Target Price$93.50
Upside/Downside11.27%
GradeOvervalued
TypeValue
Dividend Yield1.48%
Risk Assessment
Beta0.81
Volatility32.32%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.